Dr. Howard Federoff is Chief Medical Officer and Executive Vice President, Corporate Medicine and Science of Kenai Therapeutics. Recently as Chief Executive Officer of Aspen Neuroscience, he led the company through a $70 million Series A financing to advance an autologous iPSC program targeting Parkinson's disease. Subsequently, as President & Chief Executive Officer of Brooklyn ImmunoTherapeutics, he executed a pivot into iPSC immuno-oncology. Dr. Federoff co-founded Brain Neurotherapy Bio, a clinical stage company pursuing AAV gene therapy for patients with movement disorders.

Dr. Federoff is a recognized thought leader and serial entrepreneur in the field of advanced medicines for diseases of the nervous system, focused on the development of gene and cellular therapy strategies to interdict pathogenesis. As a clinician scientist he has previously served roles as Dean of Medicine, Vice Chancellor for Health Affairs, Executive Vice President for Health Sciences and Health System, President of the American Society for Experimental Therapeutics, American Society for Neural Transplant and Repair, and Vice President of the National Academy of Inventors. Dr. Federoff is an elected fellow of the American Academy of Arts and Sciences and the National Academy of Inventors, and has published more than 350 peer-reviewed, review articles, chapters and U.S. patents.

Dr. Federoff received his Doctor of Philosophy in biochemistry and Doctor of Medicine from the Albert Einstein College of Medicine.